To determine whether the synergistic effects on KRAS mutant lung cancer cells were associated with MAPK pathway, we treated a panel of KRAS(G12D) H838, KRAS(G12V) H441 and KRAS(G12S) H292cells and KRAS(WT) H838, H661and H1650 cells with AZ628 and BP-1-102 combination or BP-1-102 alone. The gene discussed is KRAS; the disease is lung carcinoma.